A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Public ClinicalTrials.gov record NCT05005442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).
Study identification
- NCT ID
- NCT05005442
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 192 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2021 (Actual)
- Primary completion
- Dec 10, 2024 (Actual)
- Completion
- Dec 10, 2024 (Actual)
- Last update posted
- Feb 19, 2026
2021 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center-Hematology ( Site 0024) | Duarte | California | 91010 | — |
| University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021 | Aurora | Colorado | 80045 | — |
| University of Chicago Medical Center ( Site 0005) | Chicago | Illinois | 60637 | — |
| Henry Ford Hospital ( Site 0003) | Detroit | Michigan | 48202 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004) | Hackensack | New Jersey | 07601 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0023) | New Brunswick | New Jersey | 08901 | — |
| University of Texas MD Anderson Cancer Center ( Site 0014) | Houston | Texas | 77030 | — |
| Medical Oncology Associates, PS ( Site 0001) | Spokane | Washington | 99208 | — |
| MEDICAL COLLEGE OF WISCONSIN ( Site 0016) | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05005442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2026 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05005442 live on ClinicalTrials.gov.